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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A145inhibiting TNF-alpha and IL-1beta associated inﬂammatory pathways
and activating TNFR2 and Integrin associated chondro-protective
pathways (Fig 3).
Fig 1A. LIPUS enhances chondrogenesis and neutralizes IL-1beta B) LIPUS
restores IL-1beta induced chondrocytes migration inhibition.
Figure 2. A)combine treatment of PGRN and LIPUS show synergistic effects
in chondrocytes anabolism. B) LIPUS þPGRN treatment enhances saffron
O staining and protect against cytokines induce cartilage degradation.
Figure 3. PGRN and LIPUS role in inhibition of inﬂammatory and activation
of chondrogenic pathways.
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IN VITRO EVALUATION AND OPTIMIZED METHODOLOGY TO
COMBINE BONE MARROW ASPIRATE CONCENTRATE WITH BST-
CARGEL® AS A NEW INJECTABLE TREATMENT FOR CARTILAGE
REPAIR
C. Marchand y, R.L. Williams z, L.M. Grover z, M. Snow x. y Piramal
Hlth.care Ltd e Bio-Orthopedics Div., Laval, QC, Canada; zUniv. of
Birmingham, Birmingham, United Kingdom; xRoyal Orthopedic Hosp.,
Birmingham, United Kingdom
Purpose: BST-CarGel® is a chitosan-based medical device used to
treat articular cartilage defects. BST-CarGel® is mixed with thepatient’s whole blood (WB) and then injected into the cartilage
defect. BST-CarGel® /WB is intended to physically stabilize the clot,
which will guide and enhance a marrow-derived repair response.
The use of bone marrow (BM) and bone marrow aspirate concen-
trate (BMAC) (containing pluripotent mesenchymal stem cells) in
the treatment of cartilage defects has recently increased in an
attempt to perform a one-stage cell based treatment. This study
optimized the method to obtain and combine BMAC with BST-
CarGel® to create a cell seeded implant which solidiﬁes in situ and
has similar in vitro properties and advantages to the BST-CarGel®/
WB product.
Methods: Bone marrow was withdrawn from the anterior iliac crest of
4 donors using 6 X 10 mL syringes pre-loaded with 1 mL sodium
heparin (1000 Units). The 60 mL heparinized BM was ﬁltered and
concentrated as per Harvest BMAC®, SmartPrep2® system method-
ology. The BMAC cell pellet was resuspended with plasma to a ﬁnal
volume of 10 mL and analyzed for cellular composition. Upon mixture
with BST-CarGel®, the coagulation was re-activated using Plateltex®-
Act (5 Units batroxobin in 500 uL 10% calcium gluconate). BST-CarGel®/
BMAC clot properties were evaluated using an in vitro model where
0.35 mL clots were generated in glass test tubes incubated at 37C and
tested for clot retraction, clotting time and clot macroscopic appear-
ance. Chitosan distribution among clots and cellular morphology were
further characterized by histology. Cellular viability of clots placed in
chondrogenic culture media were also analyzed using 3D confocal
microscopy.
Results: The average white blood cell concentration factor obtained for
BMAC was 6.9X compared to BM. The use of sodium heparin as an
anticoagulant solution led to the BST-CarGel®/BMAC in vitro properties
being similar to BST-CarGel®/WB mixture as opposed to when ACD-A
anticoagulant was used. BST-CarGel®/BMAC clots revealed a 12.3% clot
retraction with a 5 minutes (min.) clotting time (CT) compared to BST-
CarGel®/WB clots (2.6%; 15min. CT) and WB (51.9%; 15min. CT). A
homogenous distribution of chitosan among all blood components and
normal cellular morphology were observed on histology. Cell viability
was observed within the BST-CarGel®/BMAC implant and until natural
clot degradation.
Conclusions: BST-CarGel® can be combined with BMAC, as per the
methodology described to achieve an implant with similar in vitro
properties as the current marketed product. Cell viability was observed
until natural implant degradation. This combination potentially allows
for a new single stage cell based treatment to repair challenging artic-
ular cartilage defects.
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THE INFRAPATELLAR FAT PAD FROM DISEASED JOINTS INHIBITS
CHONDROGENESIS OF MESENCHYMAL STEM CELLS
W. Wei y, R. Rudjito y, N. Fahy z, K.P. Bos y, J.A. Verhaar y, S. Clockaerts y,
Y.M. Bastiaansen-Jenniskens y, G.J. Van Osch y. y Erasmus Univ. Med. Ctr.,
Rotterdam, Netherlands; zRegenerative Med. Institue, Galway, Ireland
Purpose: The microfracture procedure is used to stimulate mesen-
chymal stem cells (MSCs) to repair cartilage defects. However, instead
of hyaline cartilage, ﬁbrocartilage is formed. This could be caused by
the inﬂuence of inﬂammatory factors in the knee. The infrapatellar fat
pad (IPFP) contains pro- and anti-inﬂammatory macrophages,
secretes many factors into the joint and its secretion pattern might be
changed by joint pathology or obesity. The goal of this study was to
investigate whether factors produced by the IPFP inﬂuence chon-
drogenesis of bone marrow-derived MSCs, whether this could be
inﬂuenced by joint pathology or obesity and whether macrophages
play a role.
Methods: IPFP obtained during total knee replacement (TKR; 22
donors), anterior cruciate ligament reconstruction (ACL; 6 donors) and
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A146subcutaneous adipose tissue (SAT; 9 donors) were used to make con-
ditioned medium (CM). Additionally, CM was made of macrophages
derived from peripheral blood monocytes of 3 donors. The effect of
different types of CM on chondrogenesis of 3 human bone marrow-
derived MSC donors was evaluated by gene expression, biochemistry
and immunohistochemistry.
Results: CM from both IPFP sources and pro-inﬂammatory macro-
phages signiﬁcantly decreased gene expression of collagen type 2
(COL2A1; p<0.01) and aggrecan (ACAN; p<0.05), the COL2/collagen
type 1 (COL1A1; p<0.01) and ACAN/versican ratio (p<0.05). CM from
SAT only signiﬁcantly decreased COL2A1 (p¼0.01) and not ACAN. There
was no signiﬁcant difference between CM from TKR and ACL IPFP
donors and there was no difference between CM from lean (BMI&lt25)
or obese (BMI&gt30) IPFP donors. GAG deposition, evaluated by DMMB
assay, was not inﬂuenced by IPFP CM. Immunohistochemistry showed a
decrease in collagen type 2 staining by IPFP CM, whereas collagen type
1 staining was not inﬂuenced.
Conclusions: Factors secreted by the IPFP from diseased joints inhibit
chondrogenesis of MSCs and shift production of hyaline cartilagematrix
to a ﬁbrocartilage matrix. Type of joint pathology and obesity do not
inﬂuence this effect. The IPFP and its macrophages could be a target for
future therapies to improve the results of the microfracture procedure
in the knee.
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MIR-455 INDUCES CHONDROGENESIS BY INHIBITING RUNX2
Z. Zhang, C. Hou, F. Meng, W. Liao. First Afﬁliated Hosp. of Sun Yat-sen
Univ., Guangzhou, China
Purpose: The expression of miR-455-3p was signiﬁcantly up-regulated
in the chondrogenesis of mesenchymal stem cells, but its role still
remains unknown in different stage during chondrogenesis. Here, we
have investigated the function of miR-455-3p in chondrogenesis, and
generated a picture of the relationship with Runx2.
Methods: Chondrogenic ATDC5 cells were used. The expression of miR-
455-3p, Runx2 and related genes were tested by quantitative real-time
polymerase chain reaction (qPCR), and in situ hybridization. The func-
tion of miR-455-3p in chondrogenesis and its regulation on Runx2 were
examined by over-expressed and knocked down miR-455-3p by miR-
455-3p mimic and inhibitor treatments and luciferase assay. The
expression of miR-455-3p and related genes in ATDC5 after 14 d
chondrogenic induction was investigated with or without IL-
1bstimulation.
Results: MiR-455-3p was increased in ATDC5 from 0 d to 21d, but
then rapidly decreased, and the same expression kinetics was
detected in the development of mouse embryos. The expression level
of Runx2 was steadily increased before 21 d, thensigniﬁcantly
increased in 28 d which miR-455-3p was rapidly decreased. Fur-
thermore, miR-455-3p functions as an activator for the early chon-
drogenic differentiation from the results of Col2a1, COMP and
Adamts-5 expression after over-expressed and knocked down miR-
455-3p, and this activation of miR-455-3p was potentially through
inhibited the function of Runx2. On the other hand, IL-1b could
stimulate the expression of miR-455-3p and C/EBPb in ATDC5 after 14
d chondrogenic induction.
Conclusions:MiR-455-3p has a critical role in the early chondrogenesis
as an activator by the regulating Runx2. MiR-455-3p has a potential
function in cartilage degeneration during hypertrophic differentiation.
Our results indicates that miR-455-3p potentially alter the chondro-
genic differentiation.
